Targeted therapy in NPM1-mutated AML: Knowns and unknowns

Wang, R; Xu, P; Chang, LL; Zhang, SZ; Zhu, HH

Zhu, HH (通讯作者)，Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Hematol, Hangzhou, Peoples R China.;Zhu, HH (通讯作者)，Zhejiang Prov Key Lab Hematol Oncol Diag & Treatme, Hangzhou, Peoples R China.;Zhang, SZ; Zhu, HH (通讯作者)，China Three Gorges Univ, Dept Physiol, Med Coll, Yichang, Peoples R China.;Zhu, HH (通讯作者)，Zhejiang Univ, Canc Ctr, Hangzhou, Peoples R China.;Zhu, HH (通讯作者)，Zhejiang Univ, Zhejiang Lab Syst & Precis Med, Med Ctr, Hangzhou, Peoples R China.;Zhu, HH (通讯作者)，Zhejiang Univ, Inst Transl

FRONTIERS IN ONCOLOGY, 2022; 12 ():

Abstract

Acute myeloid leukemia (AML) is a heterogeneous disease characterized by malignant proliferation of myeloid hematopoietic stem/progenitor cells. NPM1 ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索